Non-Invasive Prenatal Testing Market Overview
The global non-invasive prenatal testing (NIPT) market size is predicted to reach $1.4 billion by 2020, growing at a CAGR of 17.6% during the forecast period. The global non-invasive prenatal testing market is growing at a significant growth rate, due to increasing average maternal age and increasing incidence of chromosome syndrome. In addition, increasing healthcare expenditure and rising demand for early and non-invasive fetal testing procedures are also driving the growth of the NIPT market.
Based on test type, the non-invasive prenatal testing market is segmented into MaterniT21 PLUS, NIFTY, Harmony test, PrenaTest, Panorama test, Verifi, and others. The MaterniT21 PLUS test holds the largest market share and by 2020, it is predicted to hold a market share of 26%. The NIFTY test is expected to witness fastest growth rate during the forecast period.
Geographically, North America dominates the global non-invasive prenatal testing market, due to increasing average maternal age, increasing healthcare expenditure, increasing demand for early and non-invasive procedure, and increasing prevalence of chromosome syndromes in the region. Among the North American countries, the U.S. leads the NIPT market in North America and it is projected to hold a market share of over 80% by 2020. It is also expected to be the fastest growing market for NIPT in the region during the forecast period.
Non-Invasive Prenatal Testing Market Dynamics
Increasing number of collaborations and partnerships is a major trend witness in the non-invasive prenatal testing market. NIPT companies are actively involved in collaborations and partnerships, for providing NIPT globally to doctors and patients. Most of these partnerships and collaborations are focused on innovative genetic solution analysis, to support education program, and for better price and faster availability of tests.
The adoption of NIPT in forthcoming years in emerging economies provides a huge growth potential for the non-invasive prenatal testing market. The growth will be driven by the growing focus on early fetal testing and increasing average maternal age. The countries, such as China and India have a large population base, still lacking primary healthcare facilities and no genetic counseling for NIPT is provided by companies.
The incidence rates of various genetic disorders and birth defects in fetus, such as Down syndrome and Edwards syndrome, are high in these countries, due to lack of awareness of genetic disorders, and high cost of the NIPT. However, healthcare facilities in these countries have not been developed up to that level, so the sample is shipped internationally for analysis by the testing companies. Moreover, various initiatives have been taken worldwide to create awareness about prenatal testing, and some of the public-sector institutes perform specific prenatal testing.
The healthcare expenditure is increasing worldwide, due to growing prevalence of diseases and innovation of new medical treatments. According to the World Health Organisation (WHO), the total healthcare expenditure is increasing globally, which is leading to the improvement in the healthcare infrastructure. This increase in healthcare expenditure leads to increase in affordability and accessibility of the new test and treatment for various conditions, which in turn is expected to support the growth of the non-invasive prenatal testing market.
There have been several developments in diagnostic and medical science. Despite these advancements, the NIPT market is undergoing some growth restraints, such as strict regulations forced by governments in various countries. Most of these regulations require NIPT manufacturers to follow norms for delivering quality medical devices consistently, to maintain the accuracy of the test. Therefore, to continue operating in the industry, the manufacturers are required to produce devices that follow standards of medical devices affiliation. This regulatory process consumes too much time for approval of medical devices, which is hampering the rapid innovation and development of the devices. Thus, stringent government norms are acting as a barrier to the non-invasive prenatal testing market.
Non-Invasive Prenatal Testing Market Competitive Landscape
BGI, LifeCodexx AG, Sequenom Inc., Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, Berry Genomics Co. Ltd., Illumina Inc., Natera Inc. and Laboratory Corporation of America Holdings are some of the major companies operating in the non-invasive prenatal testing market.